Clinical & translational immunology
Spatial and maturational characterisation of tertiary lymphoid structures predicts immunotherapy response in extensive-stage small cell lung cancer
By Wang H, Shang X, Jiang Y and 7 others.
Abstract
Objectives
Extensive-stage small cell lung cancer (ES-SCLC) remains an aggressive malignancy with limited durable responses to immune checkpoint inhibitors (ICIs) and no established predictive biomarkers. This study aimed to evaluate the prognostic and predictive value of tertiary lymphoid structures (TLSs) in patients with ES-SCLC receiving ICI-based therapy.
Methods
In this multicenter retrospective study of 180 treatment-naïve ES-SCLC patients subsequently receiving ICI-based therapy, TLSs were systematically evaluated using H&E staining, multiplex immunofluorescence, and spatial analysis to determine their prognostic and predictive value.